Protein damage and inflammation in uraemia and dialysis patients

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL.5, 2007, Pages

  Galli, Francesco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

3' nitro Tyrosine; AGEs; Dialysis; Glycation; Inflammation; Nitric oxide; Oxidation; Protein damage; Protein leaking dialysers; Proteomics; Reactive oxygen species; Uraemic toxins

Indexed keywords

AUTACOID; PLASMA PROTEIN;

BIOLOGICAL MODEL; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; HUMAN; INFLAMMATION; LEUKOCYTE; METABOLISM; MOLECULAR WEIGHT; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PROTEOMICS; RENAL REPLACEMENT THERAPY; REVIEW; UREMIA;

BLOOD PROTEINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; OXIDATIVE STRESS; PROTEOMICS; RENAL DIALYSIS; UREMIA;

EID: 34548803964     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm294     Document Type: Conference Paper

References (69)

1. Himmelfarb J. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 2005; 23: 319-330
2. Stenvinkel P, Ketteler M, Johnson RJ et al. M IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia-The good, the bad and the ugly. Kidney Int 2005; 67: 1216-1233
3. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysisassociated inflammation. Hemodial Int 2005; 9: 37-46
4. Vanholder R, Schepers E, Meert N, Lameire N. What is uremia? Retention vs oxidation. Blood Purif 2006; 24: 33-38
5. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler T. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004; 65: 2371-2379
6. Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79: 914-919
7. Galli F, Benedetti S, Floridi A et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005; 67: 750-759
8. Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17: 871-878
9. Galli F, Piroddi M, Annetti C, Aisa C, Floridi E, Floridi A. Oxidative stress and reactive oxygen species. Contrib Nephrol 2005; 149: 240-260
10. Libetta C, Zucchi M, Gori E et al. Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients. Kidney Int 2004; 65: 1473-1481
11. Horl WH, Cohen JJ, Harrington JT, Madias NE, Zusman CJ. Atherosclerosis and uremic retention solutes. Kidney Int 2004; 66: 1719-1731
12. Musial K, Zwolinska D, Polak-Jonkisz D, Berny U, Szprynger K, Szczepanska M. Serum VCAM-1, ICAM-1, and L-selectin levels in children and young adults with chronic renal failure. Pediatr Nephrol 2005; 20: 52-55
13. Ballow A, Gader AM, Huraib S, Al-Husaini K, Mutwalli A, Al-Wakeel J. Platelet surface receptor activation in patients with chronic renal failure on hemodialysis, peritoneal dialysis and those with successful kidney transplantation. Platelets 2005; 16: 19-24
14. Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res 2004; 95: 233-238
15. Galli F, Ghibelli L, Buoncristiani U et al. Mononuclear leukocyte apoptosis in haemodialysis patients: The role of cell thiols and vitamin E. Nephrol Dial Transplant 2003; 18: 1592-1600
16. Galli F, Ronco C. Oxidant stress in hemodialysis. Nephron 2000; 84: 1-5
17. Vaziri ND. Effect of chronic renal failure on nitric-oxide metabolism. Am J Kidney Dis 2001; 38: S74-S79
18. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003; 25: 207-218
19. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358-363
20. Mitrogianni Z, Barbouti A, Galaris D, Siamopoulos KC. Tyrosine nitration in plasma proteins from patients undergoing hemodialysis. Am J Kidney Dis 2004; 44: 286-292
21. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39-47
22. Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 2003; S11-S14
23. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: New products and new perspectives. Amino Acids 2003; 25: 275-281
24. Miyata T, Sugiyama S, Saito A, Kurokawa K. Reactive carbonyl compounds related uremic toxicity ('carbonyl-stress'). Kidney Int Suppl 2001; 78: S25-S31
25. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 2005; 28: 2465-2471
26. Anderson MM, Heinecke JW. Production of N(epsilon)- (carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: A role for phagocyte-derived oxidants in the formation of advanced glycation end-products during inflammation. Diabetes 2003; 52: 2137-2143
27. Thornalley PJ. Advanced glycation end-products in renal failure. J Ren Nutr 2006; 16: 178-184
28. Agalou S, Ahmed N, Thornalley PJ, Dawnay A. Advanced glycation end-product free adducts are cleared by dialysis. Ann N Y Acad Sci 2005; 1043: 734-739
29. Thornalley PJ. Measurement of protein glycation, glycated peptides and glycation free adducts. Perit Dial Int 2005; 25: 522-533
30. Floridi A, Trizza V, Paolotti P, Lucarelli C. Analytical strategy for the assessment of the protein glycation status in uremic patients by high-performance liquid chromatography. J Chromatogr A 1999; 846: 65-71
31. Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A. Mass spectrometric monitoring of albumin in uremia. Kidney Int 2000; 58: 2228-2234
32. Niwa T. Mass spectrometry for the study of protein glycation in disease. Mass Spectrom Rev 2006
33. Takayama F, Aoyama I, Tsukushi S et al. Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl)lysine in aortas of hemodialysis patients. Cell Mol Biol (Noisyle- grand) 1998; 44: 1101-1109
34. Meerwaldt R, Hartog JW, Graaff R et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end-products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3687-3693
35. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myeloperoxidase- catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 2001; 31: 1163-1169
36. Mera K, Anraku M, Kitamura K et al. Oxidation and carboxy methyl lysine-modification of albumin: Possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 2005; 28: 973-980
37. Anraku M, Kitamura K, Shinohara A et al. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004; 66: 841-848
38. Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 2001; 23: 563-571
39. Himmelfarb J, McMenamin E, McMonagle E. Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 2002; 61: 705-716
40. Yavuz A, Tetta C, Ersoy FF et al. Uremic toxins: A new focus on an old subject. Semin Dial 2005; 18: 203-211
41. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: Classification, concentration and interindividual variability. Kidney Int 2003; 63: 1934-1943
42. Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids 2003; 25: 409-417
43. Galli F, Benedetti S, Buoncristiani U et al. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int 2003; 64: 748-755
44. Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485
45. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003; 25: 283-292
46. Simm A, Bartling B, Silber RE. RAGE: A new pleiotropic antagonistic gene? Ann N Y Acad Sci 2004; 1019: 228-231
47. Witko-Sarsat V, Gausson V, Nguyen AT et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82-91
48. Morena MD, Guo D, Balakrishnan VS, Brady JA, Winchester JF, Jaber BL. Effect of a novel adsorbent on cytokine responsiveness to uremic plasma. Kidney Int 2003; 63: 1150-1154
49. Wu CC, Chen JS, Lin SH et al. Aberrant activation of the TNFalpha system and production of Fas and scavenger receptors on monocytes in patients with end-stage renal disease. Artif Organs 2005; 29: 701-707
50. Chmielewski M, Bryl E, Marzec L, Aleksandrowicz E, Witkowski JM, Rutkowski B. Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs 2005; 29: 608-614
51. Greten J, Kreis I, Wiesel K et al. Receptors for advance glycation end-products (AGE)- expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 1996; 11: 786-790
52. Randoux C, Gillery P, Georges N, Lavaud S, Chanard J. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes. Kidney Int 2001; 60: 1571-1577
53. Bordoni V, De Cal M, Rassu M et al. Protective effect of urate oxidase on uric acid induced-monocyte apoptosis. Curr Drug Discov Technol 2005; 2: 29-36
54. Cole L, Bellomo R, Davenport P et al. The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 2002; 17: 1950-1956
55. Mariano F, Fonsato V, Lanfranco G et al. Tailoring high cut-off membranes and feasible application in sepsis-associated acute renal failure: In vitro studies. Nephrol Dial Transplant 2005; 20: 1116-1126
56. Buoncristiani U, Galli F, Benedetti S et al. Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes. Contrib Nephrol 1999; 125: 133-158
57. Galli F, Beninati S, Benedetti S et al. Polymeric protein-polyamine conjugates: A new class of uremic toxins affecting erythropoiesis. Kidney Int Suppl 2001; 78: S73-S76
58. Tessitore N, Lapolla A, Arico NC et al. Effect of protein-leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels. J Nephrol 2004; 17: 707-714
59. Ishikawa I, Chikazawa Y, Sato K et al. Proteomic analysis of serum, outflow dialyzate and adsorbed protein onto dialysis membranes (polysulphone and PMMA) during hemodialysis treatment using SELDI-TOF-MS. Am J Nephrol 2006; 26: 372-380
60. Bordoni V, Piroddi M, Galli F et al. Oxidant and carbonyl stress-related apoptosis in end-stage kidney disease: Impact of membrane flux. Blood Purif 2006; 24: 149-156
61. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2570-2575
62. Winchester JF, Silberzweig J, Ronco C et al. Sorbents in acute renal failure and end-stage renal disease: Middle molecule and cytokine removal. Blood Purif 2004; 22: 73-77
63. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation end-products. Arch Biochem Biophys 2003; 419: 31-40
64. Machado AP, Pinto RS, Moyses ZP, Nakandakare ER, Quintao EC, Passarelli M. Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation endproducts. Int J Biochem Cell Biol 2006; 38: 392-403
65. Piroddi M, Depunzio I, Calabrese V et al. Oxydatively-modified and glycated proteins as candidates pro-inflammatory toxins in uremia and dialysis patients. Amino Acids 2007; (in press)
66. Weissinger EM, Kaiser T, Meert N et al. Proteomics: A novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004; 19: 3068-3077
67. Lefler DM, Pafford RG, Black NA, Raymond JR, Arthur JM. Identification of proteins in slow continuous ultrafiltrate by reversed-phase chromatography and proteomics. J Proteome Res 2004; 3: 1254-1260
68. Molina H, Bunkenborg J, Reddy GH, Muthusamy B, Scheel PJ, Pandey A. A proteomic analysis of human hemodialysis fluid. Mol Cell Proteomics 2005; 4: 637-650
69. Dalle-Donne I, Scaloni A, Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. Wiley Press, New York: 2006